Verena Gaus1, Henriette Kiep2, Martin Holtkamp2, Silke Burkert3, Friederike Kendel3. 1. Epilepsy-Center Berlin-Brandenburg, Department of Neurology, Charité-Universitaetsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany. Electronic address: verena.gaus@charite.de. 2. Epilepsy-Center Berlin-Brandenburg, Department of Neurology, Charité-Universitaetsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany. 3. Institute of Medical Psychology, Charité-Universitaetsmedizin Berlin, Luisenstr. 57, 10117 Berlin, Germany.
Abstract
PURPOSE: Anxiety and depression are frequent comorbidities in people with epilepsy (PWE), but possible gender differences are often neglected. The aim of the present study was to analyze if men and women with epilepsy differ with regard to anxiety and depressive symptoms and to identify possible predictors. METHODS: Adult consecutive PWE (N=302; 53% women) completed self-report questionnaires, including the depression module of the Patient Health Questionnaire (PHQ-9), the anxiety module of the Hospital Anxiety and Depression Scale (HADS-A) and the subscales "medication effects" and "seizure worry" of the Patient-weighted Quality of Life in Epilepsy Inventory-31-P (QOLIE-31-P). RESULTS: There was no gender difference in extent of anxiety (p=.532), which was mainly due to higher anxiety levels in men compared to the general population. The gender difference in depressive symptoms was significant (p=.009), with female patients being more affected. The most important predictors for anxiety and depressive symptoms were detrimental effects of medication (QOL medication effects) and of seizure worry (QOL seizure worry). Moreover, these predictors were more closely associated with anxiety and depressive symptoms in men. CONCLUSION: Future intervention studies could show whether providing more information about the illness and medication effects may improve anxiety and depression. Our results suggest that such interventions should be tailored to the different needs of men and women.
PURPOSE:Anxiety and depression are frequent comorbidities in people with epilepsy (PWE), but possible gender differences are often neglected. The aim of the present study was to analyze if men and women with epilepsy differ with regard to anxiety and depressive symptoms and to identify possible predictors. METHODS: Adult consecutive PWE (N=302; 53% women) completed self-report questionnaires, including the depression module of the Patient Health Questionnaire (PHQ-9), the anxiety module of the Hospital Anxiety and Depression Scale (HADS-A) and the subscales "medication effects" and "seizure worry" of the Patient-weighted Quality of Life in Epilepsy Inventory-31-P (QOLIE-31-P). RESULTS: There was no gender difference in extent of anxiety (p=.532), which was mainly due to higher anxiety levels in men compared to the general population. The gender difference in depressive symptoms was significant (p=.009), with female patients being more affected. The most important predictors for anxiety and depressive symptoms were detrimental effects of medication (QOL medication effects) and of seizure worry (QOL seizure worry). Moreover, these predictors were more closely associated with anxiety and depressive symptoms in men. CONCLUSION: Future intervention studies could show whether providing more information about the illness and medication effects may improve anxiety and depression. Our results suggest that such interventions should be tailored to the different needs of men and women.
Authors: S B Patten; J V A Williams; D H Lavorato; J L Wang; N Jetté; T T Sajobi; K M Fiest; A G M Bulloch Journal: Epidemiol Psychiatr Sci Date: 2016-10-27 Impact factor: 6.892
Authors: Kelly A Harmon; Alyssa M Day; Adrienne M Hammill; Anna L Pinto; Charles E McCulloch; Anne M Comi Journal: Pediatr Neurol Date: 2019-04-24 Impact factor: 3.372
Authors: Christine Doherty; Amy S Nowacki; Mary Pat McAndrews; Carrie R McDonald; Anny Reyes; Michelle S Kim; Marla Hamberger; Imad Najm; William Bingaman; Lara Jehi; Robyn M Busch Journal: Epilepsia Date: 2021-01-19 Impact factor: 6.740